Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Tal SellaShari I GelberPhilip D PoorvuHee-Jeong KimLaura DominiciYaileen D Guzman-ArochoLaura CollinsKathryn J RuddyRulla M TamimiJeffrey M PeppercornLidia SchapiraVirginia F BorgesSteven E ComeEllen WarnerCraig SnowDebbie M JakubowskiChristy A RussellEric P WinerShoshana M RosenbergAnn H PartridgePublished in: Breast cancer research and treatment (2020)
In young women with ER+/HER2- BC who received NCT, higher pretreatment Recurrence Score result was associated with an increased likelihood of pCR. Gene expression profile assays may have a role in decision making in young women in need of neoadjuvant therapy.
Keyphrases
- estrogen receptor
- neoadjuvant chemotherapy
- locally advanced
- early breast cancer
- lymph node
- rectal cancer
- copy number
- genome wide
- sentinel lymph node
- free survival
- genome wide identification
- radiation therapy
- high throughput
- gene expression
- breast cancer cells
- mesenchymal stem cells
- dna methylation
- smoking cessation
- cell therapy